81
Participants
Start Date
September 30, 2010
Primary Completion Date
September 30, 2012
Study Completion Date
September 30, 2012
Ranolazine
"* One 500 mg tablet in the evening on Day 1 of the period~* One 500 mg tablet, twice daily on Days 2-3 of the period~* Two 500 mg tablets (1000 mg total), twice daily from Day 4 to the end of the period (Day 15 ± 2 days)"
Placebo to match ranolazine
Placebo to match ranolazine administered in the same form and frequency as the active drug.
SPECT MPI
Gated single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) to confirm the presence of reversible exercise-induced left ventricular perfusion defect size (PDS) performed within 12 weeks prior to baseline or at the baseline visit, and at the end-of-period 1 and end-of-period 2 visits.
Exercise
Treadmill stress test
Columbia University Medical Center, New York
Dr. Michael Sacher, Massapequa
University of Pittsburgh Medical Center Cardiovascular Institute, Pittsburgh
Heritage Cardiology, Camp Hill
Alfieri Cardiology, Newark
Turku University Hospital, Turku
Delmarva Heart Research Foundation, Inc, Salisbury
Duke University Medical Center, Durham
Rambam Health Care Campus, Haifa
St. Luke's Cardiology Associates, Jacksonville
Research One, Orlando
Cardiovascular Research Center of South Florida, Miami
Cardiology Partners Clinical Research Institute, Wellington
University of Alabama at Birmingham, Birmingham
Kore Cardiovascular Research, Jackson
Research Integrity, LLC, Owensboro
Fox Valley Clinical Research Center, LLC, Aurora
Cardiovascular Imaging Technologies, Kansas City
Assuta MC, Tel Aviv
Louisiana Heart Center, Covington
Louisiana Heart Center, Slidell
Kaplan Medical Center, Rehovot
East Texas Cardiology PA, Houston
Mercury Medical, LLC, San Antonio
Barzilai Medical Center, Ashkelon
"Federico II University", Naples
Federico II University, Naples
Soroka Medical Center, Beersheba
Imperial Cardiac Center, Imperial
Mission Internal Medical Group, Mission Viejo
Central Coast Cardiology, Salinas
Clinical Trials Research, Lincoln
National University Health System, Singapore
National Heart Centre Singapore, Singapore
Androscroggin Cardiology Associates DBA Maine Research Associates, Auburn
Massachusetts General Hospital, Boston
University of Ottawa Heart Institute, Ottawa
ECOGENE-21 Clinical Trial Center, Chicoutimi Hospital, Chicoutimi
Montreal Heart Institute, Montreal
Chum Hotel Dieu, Montreal
University Hospital Kralovske Vinohrady, Prague
University Hospital Motol, Prague
Northwick Park Hospital, Watford Road, Middlesex
Lead Sponsor
Gilead Sciences
INDUSTRY